SPIA
MRSN

Steward Partners Investment Advisory’s Mersana Therapeutics MRSN Stock Holding History

Steward Partners Investment Advisory’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-9
Closed -$1.32K – 3384
2022
Q4 		$1.32K Buy
+9
New +$1.52K ﹤0.01% 3092

Other funds holding MRSN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Steward Partners Investment Advisory's MRSN Position: Q1 2023 in Review

Steward Partners Investment Advisory sold out of Mersana Therapeutics (MRSN) in Q1 2023, closing a stake of 9 shares — an estimated $1.32K sold.

Steward Partners Investment Advisory first reported a position in MRSN in Q4 2022 and held it in 1 quarter. The position peaked at $1.32K in Q4 2022. 157 funds tracked by Wall St. Rank hold MRSN as of Q1 2023.

  • Steward Partners Investment Advisory reported no remaining Mersana Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 9 Mersana Therapeutics shares in Q1 2023, an estimated $1.32K.
  • Steward Partners Investment Advisory first reported a position in Mersana Therapeutics in Q4 2022 and held it in 1 quarter.
  • Steward Partners Investment Advisory's Mersana Therapeutics position peaked at $1.32K in Q4 2022.
  • 157 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2023.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2023, filed 15 May 2023.